RPHM Reneo Pharmaceuticals Inc

USD 1.65 -0.03 -1.785714
Icon

Reneo Pharmaceuticals Inc (RPHM) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Hold

Average Analyst
Rating
stockTargetAdvisor

Hold

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 1.65

-0.03 (-1.79)%

USD 0.06B

0.12M

USD 1.43(-13.13%)

N/A

Icon

RPHM

Reneo Pharmaceuticals Inc (USD)
COMMON STOCK | NSD
USD 1.65
0.00 0
Take a Tour
stockTargetAdvisor

Hold

Average Analyst
Rating
stockTargetAdvisor

Hold

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.06B

N/A

USD 1.65

Reneo Pharmaceuticals Inc (RPHM) Stock Forecast

Show ratings and price targets of :
USD 1.43
(-13.13%)

Based on the Reneo Pharmaceuticals Inc stock forecast from 3 analysts, the average analyst target price for Reneo Pharmaceuticals Inc is USD 1.43 over the next 12 months. Reneo Pharmaceuticals Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Reneo Pharmaceuticals Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Reneo Pharmaceuticals Inc’s stock price was USD 1.65. Reneo Pharmaceuticals Inc’s stock price has changed by -6.25% over the past week, -1.20% over the past month and -83.45% over the last year.

No recent analyst target price found for Reneo Pharmaceuticals Inc
No recent average analyst rating found for Reneo Pharmaceuticals Inc

Company Overview Reneo Pharmaceuticals Inc

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxis...Read More

https://reneopharma.com

18575 Jamboree Road, Irvine, CA, United States, 92612

8

December

USD

USA

Adjusted Closing Price for Reneo Pharmaceuticals Inc (RPHM)

Loading...

Unadjusted Closing Price for Reneo Pharmaceuticals Inc (RPHM)

Loading...

Share Trading Volume for Reneo Pharmaceuticals Inc Shares

Loading...

Compare Performance of Reneo Pharmaceuticals Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for RPHM

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Reneo Pharmaceuticals Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc -3.06 (-0.76%) USD107.38B 29.93 21.06

ETFs Containing RPHM

Symbol Name RPHM's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Reneo Pharmaceuticals Inc (RPHM) Stock

Based on ratings from 3 analysts Reneo Pharmaceuticals Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Bearish. The stock has buy, sell and 3 hold ratings.

Unfortunately we do not have enough data on RPHM's stock to indicate if its a good dividend stock.

Based on targets from 3 analysts, the average taret price for RPHM is USD 1.43 over the next 12 months. The maximum analyst target price is USD 1.8 while the minimum anlayst target price is USD 1.

Unfortunately we do not have enough data on RPHM's stock to indicate if its overvalued.

The last closing price of RPHM's stock was USD 1.65.

The most recent market capitalization for RPHM is USD 0.06B.

Based on targets from 3 analysts, the average taret price for RPHM is projected at USD 1.43 over the next 12 months. This means that RPHM's stock price may go down by -13.13% over the next 12 months.

We can't find any ETFs which contains Reneo Pharmaceuticals Inc's stock.

As per our most recent records Reneo Pharmaceuticals Inc has 8 Employees.

Reneo Pharmaceuticals Inc's registered address is 18575 Jamboree Road, Irvine, CA, United States, 92612. You can get more information about it from Reneo Pharmaceuticals Inc's website at https://reneopharma.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...